Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 10/20 | 0.61 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GOT1 | P17174 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23208067 | 0.89 | STING1 (0.65) | STING1MAPTEPHX2MEN1KMT2A | |
| SCHEMBL30196046 | 0.89 | STING1 (0.65) | STING1MAPTEPHX2MEN1KMT2A | |
| SCHEMBL23208061 | 0.88 | STING1 (0.64) | STING1MAPTEPHX2MEN1KMT2A | |
| SCHEMBL23207945 | 0.87 | STING1 (0.66) | STING1MAPTEPHX2MEN1KMT2A | |
| SCHEMBL23167861 | 0.87 | STING1 (0.73) | STING1MAPTEPHX2MEN1KMT2A | |
| SCHEMBL30196056 | 0.87 | STING1 (0.62) | STING1MAPTEPHX2MEN1KMT2A | |
| SCHEMBL24835269 | 0.87 | STING1 (0.62) | STING1MAPTEPHX2MEN1KMT2A | |
| SCHEMBL23207649 | 0.86 | STING1 (0.65) | STING1MAPTEPHX2GOT1IDH1 | |
| SCHEMBL23166575 | 0.86 | STING1 (0.61) | STING1MAPTEPHX2MEN1KMT2A | |
| SCHEMBL23207773 | 0.85 | STING1 (0.60) | STING1MAPTEPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002320-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002320-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | STING1 1/4885CA12 3456/4885CA1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.